SuperworthQuidelOrtho EV/EBIT QDEL
Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2023.
- Today, Oct 23, 2026
- n/m
- an operating loss
- Last meaningful
- 113×
- Aug 2025
- 3-year median
- 40.4×
- 3-year range
- 16.2× to 140×
- Peer median
- 34.0×
QuidelOrtho has no meaningful EV/EBIT today: it made an operating loss of $824.7M over the last twelve months.
It was last meaningful in Aug 2025, at 113×.
On the days it had one over the last 3 years, its median was 40.4×, from 16.2× in Jun 2023 to 140× in May 2025.
EV/EBIT over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2025 | 113× | 106× | 140× |
| 2024 | 111× | 17.8× | 112× |
| 2023 | 25.0× | 16.2× | 25.1× |
Against its peers
Companies in Medical - Diagnostics & Research nearest QuidelOrtho's size, closest first, today.
| Company | EV/EBIT |
|---|---|
| QDELQuidelOrtho | n/m |
| NRCNRC Health | 38.8× |
| CDNACareDx | 29.3× |
| VCYTVeracyte | 27.2× |
| BLLNBillionToOne | 107× |
| LNTHLantheus | 20.6× |
| CAICaris Life Sciences | 56.4× |
| Peer median | 34.0× |
What the EV/EBIT tells you
What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.
Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.
More on QuidelOrtho
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.